通过扩大基因检测增加高危乳腺癌筛查候选者的识别
本研究对9641名女性进行包含25个基因的遗传性癌症 panel 检测,鉴定出9751个乳腺癌风险基因致病性变异,其中BRCA1/2占59.1%,ATM、CHEK2或PALB2占38.8%;仅24.7%的致病性变异携带者通过Claus模型基于家族史达到>20%终生风险阈值。结论认为扩大BRCA1/2之外的基因检测可显著增加乳腺MRI及其他风险降低措施的候选者数量,其中大多数人无法通过家族史评估被识别。
要点
- 扩大基因检测可识别更多乳腺MRI筛查候选者
- 仅24.7%的致病性变异携带者基于家族史达到>20%终生风险阈值
- BRCA1/2占致病性变异的59.1%,ATM/CHEK2/PALB2占38.8%
核心结论
- 扩大BRCA1/2之外的基因检测可显著增加乳腺MRI及其他风险降低措施的候选者数量,其中大多数人无法通过家族史评估被识别。
研究设计与样本
- 研究对女性进行包含25个基因的遗传性癌症 panel 检测,包括BRCA1/2及7个已知与>20%终生乳腺癌风险相关的额外基因(ATM、CHEK2、PALB2、TP53、PTEN、CDH1和STK11)。
- 对携带致病性变异的女性使用Claus模型评估其是否基于家族史达到>20%终生风险。
诊断标准与关键数值
- 在9641名女性中鉴定出9751个所选乳腺癌风险基因的致病性变异。
- BRCA1/2占致病性变异的59.1%,ATM、CHEK2或PALB2占38.8%。
- 所有基因中携带致病性变异的女性仅24.7%通过Claus模型达到>20%终生风险阈值。
临床应用与阅片要点
- 原文结论提示扩大基因检测可增加乳腺MRI及其他风险降低措施的候选者识别,多数候选者无法仅通过家族史评估被识别。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Breast MRI screening is recommended for women with a >20% lifetime risk for breast cancer on the basis of estimates derived from risk models dependent largely on family history. Alternatively, a >20% lifetime risk can be established through genetic testing of BRCA1 and BRCA2, as well as a growing selection of other genes associated with inherited breast cancer risk. The aim of this study was to quantify the impact of testing for genes other than BRCA1/2 and the extent to which mutation carriers in these genes would have been identified as candidates for enhanced screening on the basis of family history alone.
METHODS: Women were tested with a 25-gene hereditary cancer panel including BRCA1/2 and 7 additional genes known to be associated with a >20% lifetime risk for breast cancer (ATM, CHEK2, PALB2, TP53, PTEN, CDH1, and STK11). Women found to carry pathogenic variants (PVs) were evaluated with the Claus model to assess whether they would have been found to be at >20% lifetime risk on the basis of family history.
RESULTS: In total, 9,751 PVs in the selected breast cancer risk genes were identified in 9,641 women. BRCA1/2 accounted for 59.1% of the PVs, and 38.8% were in ATM, CHEK2, or PALB2. Only 24.7% of all women with PVs found in any gene reached the >20% lifetime risk threshold using the Claus model.
CONCLUSIONS: Expanding genetic testing beyond BRCA1/2 significantly increases the number of women who are candidates for breast MRI and other risk reduction measures, most of whom would not have been identified through family history assessment.
引用
- Rosenthal ET, Evans B, Kidd J, et al. Increased Identification of Candidates for High-Risk Breast Cancer Screening Through Expanded Genetic Testing. J Am Coll Radiol. 2016. PMID: 28011157. doi:10.1016/j.jacr.2016.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。